Replies to post #186024 on Biotech Values

[DewDiligence]

PTLA reports final phase-3 data on Annexa-A* in Xarelto reversal; all primary and secondary endpoints were achieved:

http://finance.yahoo.com/news/portola-pharmaceuticals-announces-second-part-120000557.html

PTLA reported the final phase-3 data from a similar trial in Eliquis reversal in Jun 2015 (#msg-114807697).

The phase-3 program for Annexa-A is now complete, but a phase-4 outcomes study is ongoing (#msg-109888826). PTLA expects to obtain FDA approval based on the phase-3 data only, but I wouldn’t consider this a certainty.

*f/k/a andexanet alfa.